Dr. Sijumon Kunjachan received his PhD in cancer nanomedicine from RWTH University in 2013. Currently, he is working at the Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School. His research focuses on the development and evaluation of nanomedicines for the drug delivery, imaging and radiation therapy for the treatment of cancer. Dr. Kunjachan is particularly well-known for his original exciting research on 'passive versus active tumor targeting using polymeric nanomedicines' and ‘gold nanoparticles for radiation therapy’. Based on his previous work, he has received several awards and honors, such as Radiation Research travel award, World Molecular Imaging poster prize and Elsevier Reviewer Recognition award, to name a few. He is serving as an expert reviewer for over 15 international journals including Biomaterials, Journal of Controlled Release, Biomacromolecules, Pharmaceutical Research, International Journal of Pharmaceutics, Drug Design, Development and Therapy, Clinical Pharmacology & Biopharmaceutics, Nanotechnology: Science and Applications, Clinical Pharmacology, Journal of Antimicrobial Chemotherapy, International Journal of Nanomedicine, Pharmaceutical Nanotechnology, Journal of Nuclear Medicine and Therapy and several others. Dr. Kunjachan has co-authored a book chapter titled 'Nanotheranostics' in Nanotechnology and Drug Delivery, Volume 2- Nano-Engineering Strategies and Nanomedicines against Severe Diseases. He is a member of Radiation Research Society (RadRes), American Chemical Society (ACS), European Society of Molecular imaging (ESMI) and several other professional organizations. Besides assuming role in the editorial board of Clinical Pharmacology & Biopharmaceutics journal, Dr. Kunjachan also serves as a reviewer for several international scientific grants/ fundings including the EU scientific trans-domain proposals and the National Research, Development and Innovation Office (NKFIH) of the Hungarian Academy of Sciences.

Dr. Kunjachan focuses on Radiation Oncology, Current Pharmaceutical Biotechnology, Fundamental Clinical Pharmacology, Cancer Nanotechnology and nanomedicine